Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 11/20 | 0.61 |
| ▸ | CTSS | P25774 | 9/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2849843 | 0.85 | CA12 (0.49) | MAPTALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL2851936 | 0.84 | ALDH1A1 (0.47) | MAPTALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL12799311 | 0.82 | CTSK (0.58) | CTSKCTSSCTSLCTSB | |
| SCHEMBL12799330 | 0.81 | CTSS (0.59) | CTSKCTSSCTSLCTSB | |
| SCHEMBL12799314 | 0.79 | CTSS (0.58) | CTSKCTSSCTSLTSHRCTSB | |
| SCHEMBL12799328 | 0.79 | CTSS (0.47) | CTSKCTSSCTSLCTSB | |
| SCHEMBL12799316 | 0.78 | GAA (0.52) | CTSKCTSSMAPTALDH1A1CTSL | |
| SCHEMBL14471212 | 0.78 | CTSS (0.47) | CTSKCTSSCTSLCTSB | |
| SCHEMBL13527728 | 0.78 | CTSS (0.61) | CTSKCTSSALDH1A1CTSLTSHR | |
| SCHEMBL12799326 | 0.78 | CTSS (0.48) | CTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140018549-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140018549-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | NPS PHARMACEUTICALS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-8450336-B2 | Use of D-serine derivatives for the treatment of anxiety disorders | NPS PHARMACEUTICALS, INC (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450336-B2 | Use of D-serine derivatives for the treatment of anxiety disorders | NPS PHARMACEUTICALS, INC (US) | 2013-05-28 | — | — | US | disclosed |
| US-7902401-B2 | Fluorinated compounds | NPS PHARMACEUTICALS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902401-B2 | Fluorinated compounds | NPS PHARMACEUTICALS, INC. (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100016403-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | NPS PHARMACEUTICALS, INC. | 2010-01-21 | — | — | US | disclosed |
| US-20100016403-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | NPS PHARMACEUTICALS, INC. | 2010-01-21 | — | — | US | disclosed |
| EP-1963277-B1 | FLUORINATED COMPOUNDS | NPS PHARMA INC (US) | 2010-01-20 | — | — | EP | disclosed |
| US-20090005433-A1 | Fluorinated Compounds | NPS PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20090005433-A1 | Fluorinated Compounds | NPS PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| WO-2008070994-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | NPS PHARMACEUTICALS, INC. (CA) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007076306-A1 | FLUORINATED COMPOUNDS | NPS PHARMACEUTICALS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005433-A1 | Fluorinated Compounds | CNR1, NPFFR1, AFF1 | CTSK 1009/4885CTSS 633/4885MAPT 1488/4885 |
| US-20140018549-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | OXSR1, SRR, GLRB | CTSK 3294/4885CTSS 1561/4885MAPT 4532/4885 |
| US-20100016403-A1 | USE OF D-SERINE DERIVATIVES FOR THE TREATMENT OF ANXIETY DISORDERS | OXSR1, SRR, GLRB | CTSK 3285/4885CTSS 1566/4885MAPT 4539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.